Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm’s share price had fallen to 469.8 Danish Krone (€63), its lowest level since February 2023. The stock has now declined 54% from its all-time high in June 2024, losing its position as Europe’s most valuable company to LVMH and SAP.
